HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omrix Biopharmaceuticals SA

Division of Johnson & Johnson
www.omrix.com

Latest From Omrix Biopharmaceuticals SA

Market in Focus: Surgical Sealants and Glues

Over the past few decades, the wound closure market has seen the introduction of a number of new technologies, including a variety of surgical adhesives and glues for both external and internal use to hold tissues together and/or reinforce surgical suture or staple lines. These products address a market that encompasses over 73 million surgical wounds annually in the US alone and generated sales of over $367 million in the US last year, according to Medtech Insight's recently published report US Markets for Current and Emerging Wound Closure Technologies. The US market for surgical sealants and glues is growing at an annual rate of about 3.8% and is expected to reach about $443 million in sales by 2013.
Medical Device

Novo-ZymoGenetics: The Next Roche-Genentech?

Novo Nordisk's decision to spin off ZymoGenetics in 2000 was 100% inspired by Roche's hands-off relationship with Genentech. The parent claims Zymo's R&D productivity has since increased; its recent ex-US deal with Bayer-Schering on recombinant thrombin proves that Zymo has certainly grown up and left home.
BioPharmaceutical Strategy

Surgical Sealants: Is there a Cohesive Strategy?

Surgical sealants have promise, but can a host of companies convince surgeons that these adjunctive therapies are "need to have" not "nice to have" technologies?
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Pharmaceuticals
  • Therapeutic Areas
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Robert Taub, CEO
    Israel Nur
    Stephen Guth, VP, Finance
  • Contact Info
  • Omrix Biopharmaceuticals SA
    Phone: (32) 26262323
    Avenue Louise, 140 B2
    Brussels, B-1050
    Belgium
UsernamePublicRestriction

Register